Abstract
This randomized double-blind, placebo-controlled clinical trial evaluated the anti-depressant efficacy and safety of SAGE-217, a positive allosteric modulator of GABAA receptors, in subjects with moderate-to-severe Major Depressive Disorder (MDD).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have